Literature DB >> 30597419

Current practice patterns in CIDP: A cross-sectional survey of neurologists in the United States.

Deborah Gelinas1, Jonathan Katz2, Paul Nisbet3, John D England4.   

Abstract

To evaluate how neurologists make decisions regarding chronic inflammatory demyelinating polyneuropathy (CIDP), we conducted a cross-sectional quantitative survey of 100 community neurologists in the United States. Only 13% cited using the European Federation of Neurological Societies/Peripheral Nerve Society guideline. In addition, variability in treatment approaches existed regarding the dose of IVIg used, the length of IVIg therapy before determining response, the outcome measures used to determine IVIg response, and the protocol for weaning off therapy. Forty-three percent reported giving doses that were lower than the recommended IVIg loading dose for CIDP. Many reported giving nonspecific patient education about the rationale of IVIg use and treatment duration. The finding that approximately half of community neurologists endorsed electrodiagnostic criteria that do not support CIDP diagnosis indicated difficulties relying heavily upon neurophysiologic studies in diagnostic guidelines. More education on CIDP diagnosis and treatment and a clear, actionable, clinically focused guideline would enhance best practices, particularly in the midst of high information flow and multiple guidelines. Published by Elsevier B.V.

Entities:  

Keywords:  Best practices; Chronic inflammatory demyelinating polyneuropathy; Corticosteroid; IVIg; Immunoglobulin; Survey

Mesh:

Substances:

Year:  2018        PMID: 30597419     DOI: 10.1016/j.jns.2018.11.031

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  4 in total

1.  Evaluation of the EFNS/PNS diagnostic criteria in a cohort of CIDP patients.

Authors:  Diamantis Athanasopoulos; Jeremias Motte; Thomas Grüter; Nuray Köse; Min-Suk Yoon; Susanne Otto; Christiane Schneider-Gold; Ralf Gold; Anna L Fisse; Kalliopi Pitarokoili
Journal:  Ann Clin Transl Neurol       Date:  2021-04-07       Impact factor: 4.511

Review 2.  Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy.

Authors:  Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2021-11-11       Impact factor: 7.620

3.  Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Max E Adrichem; Ilse M Lucke; Alexander F J E Vrancken; H Stephan Goedee; Luuk Wieske; Marcel G W Dijkgraaf; Nicol C Voermans; Nicolette C Notermans; Catharina G Faber; Leo H Visser; Krista Kuitwaard; Pieter A van Doorn; Ingemar S J Merkies; Rob J de Haan; Ivo N van Schaik; Filip Eftimov
Journal:  Brain       Date:  2022-06-03       Impact factor: 15.255

4.  Clinical outcome of CIDP one year after start of treatment: a prospective cohort study.

Authors:  S R M Bus; M C Broers; F Eftimov; I M Lucke; C Bunschoten; G G A van Lieverloo; M E Adrichem; R van Veen; L Wieske; H F Lingsma; H S Goedee; W L van der Pol; I N van Schaik; P A Van Doorn; B C Jacobs
Journal:  J Neurol       Date:  2021-06-26       Impact factor: 6.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.